

# Nicholas A Butowski

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/77642/publications.pdf>

Version: 2024-02-01

92  
papers

7,145  
citations

101384

36  
h-index

62479

80  
g-index

94  
all docs

94  
docs citations

94  
times ranked

9797  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. <i>Nature Medicine</i> , 2019, 25, 477-486.	15.2	932
2	Primary brain tumours in adults. <i>Lancet</i> , The, 2018, 392, 432-446.	6.3	882
3	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385.	5.1	776
4	Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. <i>Neuro-Oncology</i> , 2016, 18, 557-564.	0.6	432
5	Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 579-584.	0.8	354
6	Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 495.	3.4	325
7	Recent Advances in Therapy for Glioblastoma. <i>Archives of Neurology</i> , 2010, 67, 279-83.	4.9	234
8	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. <i>Neuro-Oncology</i> , 2019, 21, 901-910.	0.6	184
9	Diagnosis and Treatment of Recurrent High-Grade Astrocytoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 1273-1280.	0.8	164
10	Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. <i>Neuro-Oncology</i> , 2017, 19, now254.	0.6	155
11	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial. <i>Neuro-Oncology</i> , 2023, 25, 123-134.	0.6	150
12	Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1209-1217.	1.1	108
13	Advances in multidisciplinary therapy for meningiomas. <i>Neuro-Oncology</i> , 2019, 21, i18-i31.	0.6	102
14	A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). <i>Journal of Neuro-Oncology</i> , 2009, 91, 175-182.	1.4	95
15	Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. <i>Nature Genetics</i> , 2022, 54, 649-659.	9.4	93
16	Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. <i>Journal of Neuro-Oncology</i> , 2016, 130, 543-552.	1.4	90
17	Central Nervous System Cancers, Version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1191-1202.	2.3	89
18	Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. <i>Neuro-Oncology</i> , 2019, 21, 106-114.	0.6	84

#	ARTICLE	IF	CITATIONS
19	Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 140, 477-483.	1.4	82
20	MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis. <i>American Journal of Roentgenology</i> , 2018, 210, 621-628.	1.0	75
21	Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. <i>Neuro-Oncology</i> , 2011, 13, 1331-1338.	0.6	73
22	Central Nervous System Cancers, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1517-1523.	2.3	69
23	A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. <i>Journal of Neuro-Oncology</i> , 2009, 91, 183-189.	1.4	68
24	Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 295-305.	3.2	68
25	A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 984-990.	0.6	62
26	Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 838-847.	0.6	60
27	The genetic landscape of gliomas arising after therapeutic radiation. <i>Acta Neuropathologica</i> , 2019, 137, 139-150.	3.9	57
28	A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. <i>Nature Communications</i> , 2018, 9, 810.	5.8	56
29	Treatment options for recurrent high-grade gliomas. <i>CNS Oncology</i> , 2017, 6, 61-70.	1.2	51
30	Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. <i>Neuro-Oncology</i> , 2021, 23, 1872-1884.	0.6	48
31	A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 1454-1459.	0.4	47
32	Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2011, 13, 119-131.	0.6	47
33	The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. <i>Neurosurgery</i> , 2015, 77, 248-253.	0.6	47
34	Mouse models of glioblastoma for the evaluation of novel therapeutic strategies. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab100.	0.4	47
35	Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience. <i>Journal of Neuro-Oncology</i> , 2016, 126, 193-200.	1.4	45
36	Phase II trial of 7 days on/7 days off temozolomide for recurrent high-grade glioma. <i>Neuro-Oncology</i> , 2014, 16, 1255-1262.	0.6	44

#	ARTICLE	IF	CITATIONS
37	Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas. <i>Cancer</i> , 2017, 123, 4631-4639.	2.0	43
38	The Effect of Molecular Diagnostics on the Treatment of Glioma. <i>Current Oncology Reports</i> , 2017, 19, 26.	1.8	40
39	Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2016, 130, 571-579.	1.4	39
40	Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor. <i>Acta Neuropathologica Communications</i> , 2020, 8, 151.	2.4	35
41	Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa142.	0.4	35
42	Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: A phase I study. <i>Neuro-Oncology</i> , 2010, 12, 608-613.	0.6	34
43	A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 603-610.	1.1	32
44	Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	32
45	Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2270-2277.	3.2	30
46	Risk factors of radiotherapy-induced cerebral microbleeds and serial analysis of their size compared with white matter changes: A 7T MRI study in 113 adult patients with brain tumors. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 868-877.	1.9	25
47	Association of early changes in <sup>1</sup> H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen. <i>Neuro-Oncology</i> , 2017, 19, now159.	0.6	24
48	Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab. <i>Journal of Neuro-Oncology</i> , 2016, 130, 171-179.	1.4	24
49	Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 3916-3925.	3.2	24
50	Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma. <i>Neurosurgery</i> , 2015, 62, 160-165.	0.6	23
51	Small Molecule and Monoclonal Antibody Therapies in Neurooncology. <i>Cancer Control</i> , 2005, 12, 116-124.	0.7	22
52	Interventional MRI-guided catheter placement and real time drug delivery to the central nervous system. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 635-639.	1.4	21
53	Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas. <i>Acta Neuropathologica</i> , 2019, 138, 877-881.	3.9	21
54	Early tumor growth between initial resection and radiotherapy of glioblastoma: incidence and impact on clinical outcomes. <i>Journal of Neuro-Oncology</i> , 2017, 134, 213-219.	1.4	21

#	ARTICLE	IF	CITATIONS
55	Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2007, 85, 87-94.	1.4	20
56	Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme. <i>Neuro-Oncology</i> , 2013, 15, 480-489.	0.6	20
57	Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60. <i>Journal of Neuro-Oncology</i> , 2019, 141, 383-391.	1.4	18
58	Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac025.	0.4	18
59	Endpoints for clinical trials and revised assessment in neuro-oncology. <i>Current Opinion in Neurology</i> , 2012, 25, 780-785.	1.8	17
60	NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2919-2929.	1.9	17
61	Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type Glioblastoma. <i>Neurosurgery</i> , 2022, 90, 124-130.	0.6	17
62	Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival. <i>Neuro-Oncology Practice</i> , 2019, 6, 364-374.	1.0	16
63	Glial tumors: the current state of scientific knowledge. <i>Clinical Neurosurgery</i> , 2006, 53, 106-113.	0.2	16
64	The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollment. <i>Journal of Neuro-Oncology</i> , 2020, 148, 131-139.	1.4	15
65	The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma. <i>Academic Radiology</i> , 2016, 23, 1073-1082.	1.3	14
66	The immunohistochemical, DNA methylation, and chromosomal copy number profile of cauda equina paraganglioma is distinct from extra-spinal paraganglioma. <i>Acta Neuropathologica</i> , 2020, 140, 907-917.	3.9	13
67	Immunostimulants for Malignant Gliomas. <i>Neurosurgery Clinics of North America</i> , 2010, 21, 53-65.	0.8	12
68	Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab065.	0.4	12
69	Chordoid glioma of the third ventricle: report of a rapidly progressive case. <i>Journal of Neuro-Oncology</i> , 2017, 132, 487-495.	1.4	10
70	Using genomics to guide treatment for glioblastoma. <i>Pharmacogenomics</i> , 2018, 19, 1217-1229.	0.6	10
71	Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes. <i>Neuro-Oncology</i> , 2022, 24, 1749-1762.	0.6	10
72	Medical Management of Brain Metastases. <i>Neurosurgery Clinics of North America</i> , 2011, 22, 27-36.	0.8	8

#	ARTICLE	IF	CITATIONS
73	Anti-angiogenic therapy in glioma. <i>Clinical and Translational Oncology</i> , 2011, 13, 294-300.	1.2	8
74	Clinical trial endpoints for patients with gliomas. <i>Neuro-Oncology Practice</i> , 2017, 4, 201-208.	1.0	7
75	A systematic review and meta-analysis examining the effects of cannabis and its derivatives in adults with malignant CNS tumors. <i>Neuro-Oncology Practice</i> , 2020, 7, 376-383.	1.0	6
76	A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma. <i>Journal of Neuro-Oncology</i> , 2021, 153, 447-454.	1.4	6
77	Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply. <i>Lancet Oncology</i> , 2017, 18, e709-e710.	5.1	5
78	Attitudes toward fertility and fertility preservation in women with glioma. <i>Neuro-Oncology Practice</i> , 2019, 6, 218-225.	1.0	5
79	ATIM-11. PHASE 2 TRIAL OF SL-701, A NOVEL IMMUNOTHERAPY COMPRISED OF SYNTHETIC SHORT PEPTIDES AGAINST GBM TARGETS IL-13R $\alpha$ 2, EphA2, AND SURVIVIN, IN ADULTS WITH SECOND-LINE RECURRENT GBM: INTERIM RESULTS. <i>Neuro-Oncology</i> , 2016, 18, vi20-vi20.	0.6	4
80	Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials. <i>Translational Oncology</i> , 2015, 8, 446-455.	1.7	3
81	The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab035.	0.4	3
82	ATIM-10. PHASE 2 TRIAL OF SL-701, A NOVEL IMMUNOTHERAPY COMPRISED OF SYNTHETIC SHORT PEPTIDES AGAINST GBM TARGETS IL-13R $\alpha$ 2, EphA2, AND SURVIVIN, IN ADULTS WITH SECOND-LINE RECURRENT GBM. <i>Neuro-Oncology</i> , 2017, 19, vi28-vi28.	0.6	2
83	Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab082.	0.4	2
84	General and neurological complications of targeted therapy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 105, 937-945.	1.0	1
85	A targeted gene expression biomarker and association with meningioma outcomes and radiotherapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2007-2007.	0.8	1
86	ACTR-33. A PHASE I STUDY OF CONVECTION-ENHANCED DELIVERY OF LIPOSOMAL-IRINOTECAN USING REAL-TIME IMAGING WITH GADOLINIUM IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA. <i>Neuro-Oncology</i> , 2016, 18, vi9-vi9.	0.6	0
87	ACTR-32. A PROSPECTIVE PHASE II STUDY OF EVEROLIMUS FOR RECURRENT ADULT LOW GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2016, 18, vi8-vi9.	0.6	0
88	PATH-08. THE IVY GLIOBLASTOMA PATIENT ATLAS - A NOVEL CLINICAL AND RADIO-GENOMICS RESOURCE FOR EARLY PHASE CLINICAL TRIAL DESIGN AND INTERPRETATION. <i>Neuro-Oncology</i> , 2018, 20, vi159-vi159.	0.6	0
89	Phase 2 trial of newly diagnosed high-grade glioma treated with concurrent radiation therapy, temozolomide, and BMX-001. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS2069-TPS2069.	0.8	0
90	A study of neo-adjuvant and adjuvant ofra-vec (VB-111) for treatment of surgically accessible recurrent GBM. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2075-TPS2075.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Clinical application of a functional 3D ex vivo test to predict therapeutic response in patients with HGG: A progression-free survival analysis.. Journal of Clinical Oncology, 2022, 40, 2031-2031.	0.8	0
92	Digital monitoring and assessments in patients with glioblastoma.. Journal of Clinical Oncology, 2022, 40, 2045-2045.	0.8	0